C. Hézode

511 total citations
37 papers, 309 citations indexed

About

C. Hézode is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, C. Hézode has authored 37 papers receiving a total of 309 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Hepatology, 19 papers in Epidemiology and 8 papers in Infectious Diseases. Recurrent topics in C. Hézode's work include Hepatitis C virus research (23 papers), Liver Disease Diagnosis and Treatment (9 papers) and Hepatitis B Virus Studies (9 papers). C. Hézode is often cited by papers focused on Hepatitis C virus research (23 papers), Liver Disease Diagnosis and Treatment (9 papers) and Hepatitis B Virus Studies (9 papers). C. Hézode collaborates with scholars based in France, United States and Germany. C. Hézode's co-authors include Jean–Michel Pawlotsky, Stéphane Chevaliez, Daniel Dhumeaux, Marc Bourlière, Dominique Larrey, Abdelhakim Ahmed‐Belkacem, Stanislas Pol, Rozenn Brillet, Sophie Lotersztajn and Didier Samuel and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and Hepatology.

In The Last Decade

C. Hézode

34 papers receiving 296 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Hézode France 9 273 251 55 22 20 37 309
S. Gordon United States 9 213 0.8× 221 0.9× 59 1.1× 6 0.3× 16 0.8× 14 295
Céline Dorival France 8 145 0.5× 146 0.6× 22 0.4× 26 1.2× 16 0.8× 28 228
Anne Varaut France 8 356 1.3× 383 1.5× 51 0.9× 3 0.1× 14 0.7× 10 446
J.T. Brouwer Netherlands 8 230 0.8× 197 0.8× 15 0.3× 15 0.7× 39 1.9× 14 285
Toby Delahooke United Kingdom 8 195 0.7× 208 0.8× 15 0.3× 4 0.2× 11 0.6× 15 300
Feng Su United States 8 337 1.2× 322 1.3× 44 0.8× 2 0.1× 12 0.6× 13 428
T.J. Layden United States 4 419 1.5× 434 1.7× 40 0.7× 12 0.5× 10 0.5× 7 503
Rachele Rapetti Italy 8 212 0.8× 237 0.9× 26 0.5× 5 0.2× 18 0.9× 15 306
P. Marks United Kingdom 7 223 0.8× 195 0.8× 60 1.1× 10 0.5× 55 2.8× 17 316
Hiroshi Kamitsukasa Japan 9 206 0.8× 209 0.8× 46 0.8× 2 0.1× 13 0.7× 18 298

Countries citing papers authored by C. Hézode

Since Specialization
Citations

This map shows the geographic impact of C. Hézode's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Hézode with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Hézode more than expected).

Fields of papers citing papers by C. Hézode

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Hézode. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Hézode. The network helps show where C. Hézode may publish in the future.

Co-authorship network of co-authors of C. Hézode

This figure shows the co-authorship network connecting the top 25 collaborators of C. Hézode. A scholar is included among the top collaborators of C. Hézode based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Hézode. C. Hézode is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hézode, C., et al.. (2019). Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy. SHILAP Revista de lepidopterología. 1 indexed citations
2.
3.
Abergel, Armand, C. Hézode, Tarik Asselah, et al.. (2018). High efficacy and safety of grazoprevir and elbasvir for 8 weeks in treatment-naive, non-severe fibrosis HCV GT1b-infected patients: Interim Results of the STREAGER Study. Journal of Hepatology. 68. S110–S110. 8 indexed citations
4.
Poordad, Fred, Stanislas Pol, Armen Asatryan, et al.. (2017). MAGELLAN-1, Part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic hepatitis C virus genotype 1 or 4 and prior direct-acting antiviral treatment failure. Journal of Hepatology. 66(1). S83–S84. 13 indexed citations
5.
6.
Agarwal, Kosh, Yves Horsmans, William Sievert, et al.. (2013). 798 EFFICACY OF TELAPREVIR DOSED TWICE DAILY VERSUS EVERY 8 HOURS BY IL28B GENOTYPE: RESULTS FROM THE PHASE III OPTIMIZE STUDY. Journal of Hepatology. 58. S326–S326. 6 indexed citations
7.
Hézode, C., Xavier Causse, Dominique Larrey, et al.. (2013). 748 VIROLOGICAL RESPONSE AND TOLERANCE OF TENOFOVIR DF (TDF) IN THE ELDERLY IS SIMILAR TO YOUNGER PATIENTS IN REAL LIFE PRACTICE. Journal of Hepatology. 58. S303–S303. 4 indexed citations
8.
Buggisch, Peter, Marı́a Buti, Kosh Agarwal, et al.. (2013). OPTIMIZE trial: Non-inferiority of twice-daily telaprevir versus administration every 8 hours in treatment-naïve, genotype 1 HCV infected patients. Zeitschrift für Gastroenterologie. 51(8). 11 indexed citations
9.
Marcellin, Patrick, Fabien Zoulim, Xavier Causse, et al.. (2012). 531 TENOFOVIR DF TREATMENT IS SAFE AND WELL TOLERATED IN CHRONIC HEPATITIS B (CHB) PATIENTS WITH BASELINE DECREASED GLOMERULAR FILTRATION RATE. Journal of Hepatology. 56. S210–S210. 5 indexed citations
10.
11.
12.
Hézode, C., Juliette Foucher, J.‐P. Bronowicki, et al.. (2009). 123 EFFICACY AND SAFETY OF AN INTENSIFIED REGIMEN OF PEGYLATED INTERFERON ALFA-2A PLUS RIBAVIRIN IN HCV GENOTYPE 1 NON-RESPONDERS: AN INTERIM ANALYSIS OF THE SYREN TRIAL. Journal of Hepatology. 50. S50–S50. 1 indexed citations
13.
Hézode, C., Élie Serge Zafrani, Françoise Roudot‐Thoraval, et al.. (2007). [17] CANNABIS USE AS AN INDEPENDENT PREDICTOR OF SEVERE STEATOSIS DURING CHRONIC HEPATITIS C. Journal of Hepatology. 46. S10–S10. 1 indexed citations
14.
Pallier, C., et al.. (2007). [55] COMPLEX DYNAMICS OF HEPATITIS B VIRUS RESISTANCE TO ADEFOVIR DIPIVOXIL. Journal of Hepatology. 46. S26–S26. 12 indexed citations
15.
Chevaliez, Stéphane, Rozenn Brillet, C. Hézode, Daniel Dhumeaux, & Jean–Michel Pawlotsky. (2006). P.228 Assessment of ribavirin mutagenic properties in vivo and the influence of interferon alpha-induced reduction of hepatitis C virus RNA load upon therapy. Journal of Clinical Virology. 36. S132–S132. 3 indexed citations
16.
Pawlotsky, Jean–Michel, Rozenn Brillet, C. Hézode, & Daniel Dhumeaux. (2004). 62 Is ribavirin antiviral effect in humans mediated by mutagenic properties resulting in error catastrophe?. Journal of Hepatology. 40. 23–23. 4 indexed citations
17.
Hézode, C., Françoise Roudot‐Thoraval, Pascale Grenard, et al.. (2004). 68 Daily cannabis smoking as a risk factor for fibrosis progression in chronic hepatitis C. Journal of Hepatology. 40. 25–25. 30 indexed citations
18.
Zeuzem, Stefan, Jean–Michel Pawlotsky, Ioannis Goulis, et al.. (2003). 317 International multicenter, randomized, controlled study comparing standard versus dynamically individualized treatment in patients with chronic hepatitis C (DITTO-HCV) project). Hepatology. 38. 310–310. 6 indexed citations
19.
Hézode, C., Françoise Roudot‐Thoraval, Sylvie Naveau, et al.. (2000). Alpha 2A interferon monotherapy in patients with chronic hepatitis C and repeatedly normal aminotransferase levels. Journal of Hepatology. 32. 109–109. 1 indexed citations
20.
Duvoux, Christophe, et al.. (2000). [Synopsis: liver transplantation in adults: indications, results and postoperative follow-up].. PubMed. 24(5). 557–66. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S. Gordon Breakdown of academic impact, for papers by Céline Dorival Breakdown of academic impact, for papers by Anne Varaut Breakdown of academic impact, for papers by J.T. Brouwer Breakdown of academic impact, for papers by Toby Delahooke Breakdown of academic impact, for papers by Feng Su Breakdown of academic impact, for papers by T.J. Layden Breakdown of academic impact, for papers by Rachele Rapetti Breakdown of academic impact, for papers by P. Marks Breakdown of academic impact, for papers by Hiroshi Kamitsukasa
Rankless by CCL
2026